INTRODUCTION
Infantile malignant Osteopetrosis (Autosomal Recessive Osteopterosis, ARO, MIM 259700) is a genetically heterogenous autosomal recessive disorder of bone metabolism, which, if untreated, has a fatal outcome. Early death is common, with only 30% survival at 6 years of age. [1] [2] [3] It is characterized by generalized osteosclerosis, secondary to bone marrow failure with anemia and thrombocytopenia with subsequent extramedullary hematopoiesis and impaired vision and hearing due to encroachment of nerve canals. [1] [2] [3] Other presentations include failure to thrive and recurrent infections, both secondary to the underlying anemia and bone marrow involvement. A defect in macrophage killing of bacteria may account for recurrent and sometimes overwhelming infection. Hypocalcemic seizures, 4 excessive bruising, nontraumatic fractures, abnormal craniofacial appearance (macrocephaly and frontal bossing) and snuffling because of disruption of nasal architecture are also less common complaints. 3 Neurological involvement can range from mild developmental delay to generalized neurodegeneration, which may be associated with primary retinal degeneration. 1 The exact incindence of autosomal recessive osteopetrosis is not known, but is estimated to be 1 in 200,000. 5 It should be distinguished from the autosomal dominant adult disease (ADOI, MIM 607634 and ADOII, MIM 166600) and the carbonic anhydrase II deficiency, which is associated with renal tubular acidosis and cerebral calcification (MIM 259730). In recent decades, a number of intermediate forms associated with mild autosomal recessive inheritance (MIM 259710) and mild symptoms have been reported (MIM 259710). 6 Recently, genetic and mutational analysis found several mutations in malignant osteopetroses. Especially two genes, ATP6i (TCIRG1) and ClCN7, have been identified to be associated with human ARO. ATP6i gene, encoding the a3 subunits of the vacuolar proton pump, which mediates the acidification of the bone/osteoclast interface, is responsible for about 58% of patients affected by ARO. 2 Few cases of ARO have been ascribed to mutations in the chloride channel 7 (ClCN7) gene on chromosome 16p13.3, which accounts for all autosomal dominant type II cases reported. ClCN7 provides chloride conductance required for efficient proton pumping in the osteoclast ruffled membrane. 7 Hematopoietic stem-cell transplantation presently seems to be the most effective therapy for ARO, because it provides normal osteoclast precursors. 8 However, high doses of active vitamin D, interferon-g (IFN-g) and steroid therapies also have been reported to be effective.
In this investigation, we describe a patient with apparent clinical features of ARO bearing two mutations in ClCN7 gene, who died of overwhelming sepsis at 5 months of age despite medical management with high-dose vitamin D, IFN-g, and steroid.
Patient
A 29-year-old multigravida woman was referred for prenatal care and monitoring platelet count at 32 þ 2 weeks of gestational age because her first baby, male, died of sepsis and massive gastrointestinal bleeding associated with incorrectable thrombocytopenia at 36th day after birth, suggestive of ''alloimmune thrombocytopenia of newborn'' diagnosis. Her platelet count on the peripheral blood examination was normal and there was no evidence of the presence of antiplatelet antibody nor platelet-specific antigen.
On 34 þ 2 weeks of gestational age, she delivered a female preterm baby by emergency cesarian section because of low platelet count by cordocentesis, 44 x 10 9 /l. At birth, the baby presented moderate hepatosplenomegaly and thrombocytopenia, platelet count was 52x10 9 /l. The baby was given a platelet transfusion with her maternal platelets. In addition, intravenous immunoglobulin (IVIG) was given at a dose of 1 g/kg/ day for 2 days started on the first day of life. Although the treatments were repeated several times for 2 weeks, there was no clinical improvement. Peripheral blood smear showed normochromic, normocytic anemia with nucleated RBCs, leftshifted neutrophils with atypical lymphocytes and moderately decreased number of platelets.
Radiologic examinations revealed diffuse osteosclerotic change in the skull and limbs with obliteration of the bone marrow space. At the 30th day of life, we found bilateral fractures of the humerus by chance, suggestive of pathologic fractures (Figure 1 ). The CT of the brain showed a mild cortical atrophy associated with bilateral narrowing of optic canals (Figure 2) . Her serum calcium level was low normal (7.3 mg/dl), and inorganic phosphorus level was also slightly decreased (3.2 mg/dl). Her serum alkaline phosphatase (ALP) activity was 391 IU/l.
The entire ClCN7 gene was amplified at genomic level with appropriate primers (Accession Number genomic sequence AL031600) and sequencing was performed directly on the PCR products. The sequence analysis revealed that the patient bore two mutations in ClCN7 gene: (1) a deletion of an A at nucleotide 17631, in the paternally derived allele causing a frameshift and a premature stop codon at codon 395, and (2) an intronic point mutation G23742A (in the canonical dinucleotide donor splicing site of exon 21) in the maternal allele. cDNA analysis showed that this splicing mutation caused the skipping of the exon21 ( Figure 3 ).
As no HLA-identical donor was found and her parents hesitated for a bone marrow transplantation, high-dose calcitriol therapy combined with administration of prednisolone (1 mg/kg, b.i.d.) and IFN-g (1.5 mg/kg/dose subcutaneously, three times per week) was begun under a low-Ca diet.
During the treatment, she showed snuffling and seizure, which was controlled with oral anticonvulsants. She also presented marked frontal bossing with visual impairement. However, the frequency of transfusion of platelets and packed RBCs was markedly reduced, about once per month. The CT of the brain, performed at 4 months of age (3 months of corrected age, CA) showed the sign of progressive compression of optic nerve.
At 5 months of age (4 months of CA), she died of pneumonia and rapid full-blown sepsis.
DISCUSSION
Osteopetrosis has a high mortality rate in the first 2 years of life. Visual impairment, which is present in 75% of patients by the first year of life is the most common and often earliest neurological manifestation of ARO.
In neonatal presentation, although hematologic impairments such as anemia and thrombocytopenia are thought to be due to hypersplenism and extravascular hemolysis, the exact pathogenesis has not yet been defined. Papoff et al. 9 considered that Thrombopoietin (Tpo) levels may be useful to explain the underlying mechanism of decreased platelet counts. Tpo is the principal regulator of megakaryocytopoiesis and platelet production. 10 In vitro studies have also shown that Tpo decreases the bone-resorbing activity by inhibiting the osteoclast cell formation. 7 Inverse correlation between Tpo levels and platelet counts in osteopetrosis suggests that megakaryocyte deficiency is an important contributor to thrombocytopenia 9 . However, in our patient, we did not measure the Tpo levels.
Chloride channels play important roles in the plasma membrane and in intracellular organelles. Kornak et al. 11 reported that mice deficient for the ubiquitously expressed ClCN7, Cl(À) channel, show severe osteopetrosis and retinal degeneration despite normal numbers of osteoclasts. They fail to resorb bone because they cannot properly acidify the extracellular resorption lacuna. Chloride channels are highly expressed in the ruffle membrane of osteoclasts, formed by the fusion of H( þ )-ATPase-containing vesicles, and act in concert with the vacuolar proton pump, by providing the chloride conductance required for an efficient electrical shunt of the proton pump.
There are four major genes responsible for human ARO, such as carbonic anhydrase II, a3 subunit of the vacuolar proton pump, ClCN7 and gray-lethal. 2, [11] [12] [13] [14] [15] [16] The majority of ARO, about 58% of patients, is explained by defect of vacuolar proton pump.
2 Until now, ClCN7 gene has been shown to be mutated in only two cases of ARO. 11, 12 In our patient, at first, the main clinical problem was thrombocytopenia, then anemia and nontraumatic fractures with sclerotic radiologic findings led us to diagnose the patient as ARO.
The mutations analysis of the ClCN7 gene allowed us to confirm the ARO diagnosis. In conclusion, although thrombocytopenia is a common problem in sick newborns, we also should care about bone marrow failure or replacement as one of probable causes.
